European Pharmaceutical Review

NOVEMBER 2, 2023

This evidence included comparisons of the products on an analytical level using chemical and biological tests and assays that confirmed similarity in the structural and functional features of Wezlana and Stelara, as well as comparative human pharmacokinetic data, clinical immunogenicity data and other clinical safety and effectiveness data.

Food and Drug Administration 98

Food and Drug Administration FDA Side effects Safety 98

European Pharmaceutical Review

OCTOBER 24, 2024

The biologic treatment was granted approval as Kisunla (donanemab-azbt) in the US by the Food and Drug Administration (FDA) in July 2024. The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources,” explained Helen Knight, Director of medicines evaluation at NICE.

Food and Drug Administration 52

Food and Drug Administration Side effects Medicine Patients 52

European Pharmaceutical Review

DECEMBER 22, 2023

It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain. Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024.

Food and Drug Administration 98

Food and Drug Administration Side effects Safety Food 98

European Pharmaceutical Review

OCTOBER 17, 2024

In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. These factors may increase the likelihood that patients and caregivers carry it regularly. Poster Presented at the 2024 AAAAI Annual meeting, DC, US.

Food and Drug Administration 121

Food and Drug Administration Medicine Consulting Food 121

PM360

JUNE 24, 2024

Deerfield Agency discusses patient centricity in rare disease and their perspectives with Tim Pigot, Chief Commercial Officer of Aerovate, and Colleen Brunetti, PAH patient and advocate. Too often, companies delay engaging the patient community until they have early evidence of a drug’s potential benefit.

Patients 52

Patients Education Side effects Management 52

PM360

JUNE 24, 2024

Patients can look forward to electronic assistance that can return their voice or other lost abilities. When entering a patient’s conditions into the chatbot, it responds with a list of recommended drugs. It also flags possible side effects and interactions between drugs.

Healthcare 52

Healthcare Healthcare Patients Side effects 52

European Pharmaceutical Review

NOVEMBER 5, 2024

New data presented at Psych Congress 2024 has shown that the olanzapine long-acting injectable (LAI) TEV-‘749 / mdc-TJK demonstrated “significant improvement” in social functioning and quality of life in adults with schizophrenia. This was based on findings from the initial period (up to week 8) of the Phase III SOLARIS trial.

Side effects 52

Side effects Safety Medical Medicine 52

pharmaphorum

DECEMBER 5, 2022

A medium or high dose of its lead, CD19-targeting CAR-NK therapy candidate NKX19 achieved complete responses in seven out of 10 patients with relapsed or refractory non-Hodgkin lymphoma (NHL), driving their cancer into remission. Those will get underway in 2024.

Side effects 86

Side effects Safety Patients Leads 86

Clarivate

MAY 1, 2024

We took a look at these drugs’ impact on the medtech sector for our forthcoming report, Medtech Trends to Watch in 2024 , and found a more nuanced picture. These drugs could also enlarge the pool of candidates for major joint surgeries as patients become more physically active after achieving weight reductions, as Stryker has noted.

Side effects 59

Side effects Physicians Medical Patients 59

PM360

SEPTEMBER 30, 2024

Now more than ever, oncology innovators need to ground early commercial decision making in a deep understanding of how the science of their product directly solves a need that patients with cancer will have at time of launch. Until recently, commercialization of an oncology product was similar to any other pharmaceutical launch.

Side effects 52

Side effects Marketing Patients Specialization 52

PM360

OCTOBER 22, 2024

In this issue, we take a closer look at adherence and compliance regarding patients and medications along with their involvement with pharmaceutical companies. What strategies are most effective in improving patient adherence to prescribed medication regimens, and how can pharmaceutical companies support these strategies?

Education 52

Education Side effects Medical Patients 52

PM360

OCTOBER 22, 2024

For researchers developing new medicines and therapies, RWD gives us an understanding of patients’ actual experiences outside of carefully controlled clinical trials. Clinical trials are also more likely to be conducted at academic medical centers, so patients living in rural areas are less likely to participate.

Side effects 52

Side effects Patients Prescription Healthcare 52

Pharmaceutical Technology

APRIL 21, 2023

It will pay another $10m in instalments through to September 2024. Blue Water chairman and CEO Joseph Hernandez stated: “With millions of men suffering from BPH and facing adverse side effects associated with current treatments, we are excited to support those patients and make Entadfi readily available for all.

Food and Drug Administration 52

Food and Drug Administration Side effects Distribution Sales 52

European Pharmaceutical Review

SEPTEMBER 5, 2024

Cancer-associated fibroblasts, and their effects of the immune activity in the tumour, are considered one of the main reasons why around four out of five patients do not benefit from immunotherapies such as checkpoint inhibitors. For the 28 patients who received only pembrolizumab, the OS was 58 percent.

Medicine 59

Medicine Side effects Marketing Patients 59

Pharmaceutical Technology

JUNE 16, 2023

Since some of the patients with major clinical depression do not respond sufficiently to one or more antidepressants, there is a need for new treatments, said Buntinx. Due to this, adjunctive treatments are used as part of a patient’s treatment regimen. While the drug is marketed in other countries, it is not registered in the US.

Food and Drug Administration 52

Food and Drug Administration Side effects Safety Recruitment 52

Pharmaceutical Technology

JULY 28, 2022

Discontinuation or non-adherence to antipsychotic treatment is the most common cause of relapse in patients diagnosed with schizophrenia. As such, patients are typically offered continuous antipsychotic pharmacotherapy to prevent recurring episodes of psychosis. and 82.7%, respectively, of patients using oral aripiprazole.

Prescription 98

Prescription Side effects Patients Management 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Up to fifty percent of IgAN patients progress to end-stage renal disease, requiring dialysis or transplant.

Food and Drug Administration 98

Food and Drug Administration Leads Patients Side effects 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Up to fifty percent of IgAN patients progress to end-stage renal disease, requiring dialysis or transplant.

Food and Drug Administration 98

Food and Drug Administration Leads Patients Side effects 98

PM360

SEPTEMBER 30, 2024

Engaging with healthcare professionals and patients through educational initiatives and open dialogue helps to demystify complex information and foster a sense of reliability between the two. PM360 asked a few specialists to share their intake on building trust equity with patients in the industry. Trust therefore is a winner’s issue.

Ethics 59

Ethics Pharma Side effects Healthcare 59

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. If all goes well, the aim is to bring resiniferatoxin to market in 2025.

Side effects 52

Side effects Recruitment Patients Safety 52

European Pharmaceutical Review

JULY 18, 2024

1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of side effects. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.

Food and Drug Administration 59

Food and Drug Administration Engineering Pharmacology Side effects 59

pharmaphorum

JUNE 23, 2022

The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis.

Side effects 79

Side effects Pharma Marketing Patients 79

Evolve Your Success

FEBRUARY 13, 2024

— Watch the episode here Listen to the podcast here Surviving Cancer And Making An Impact To Cancer Patients’ Lives With Rob Ciaramitaro In this episode, we have with us another special guest and he goes by the name of Rob Ciaramitaro. Diagnostic products can change when patients discover their diseases.

Patients 64

Patients Sales Medical sales Doctors 64

pharmaphorum

SEPTEMBER 14, 2022

After years of stagnation in the treatment of neurodegenerative disorder amyotrophic lateral sclerosis (ALS), patients in the US could soon have two new treatment options – but their pricing is already raising red flags.

Side effects 64

Side effects FDA Medical Patients 64

pharmaphorum

SEPTEMBER 15, 2022

In the aftermath of that results, it modified the design of its second phase 3 trial – TRANQUILITY 2 – to increase the number if patients enrolled and add in tear production measured suing the Schirmer test as a co-primary endpoint. Sales were nevertheless solid at $468 million and $1.29 billion respectively last year.

FDA 52

FDA Side effects Prospecting Patients 52

Pharmaceutical Representative Training

OCTOBER 9, 2024

They may have valid concerns about the product’s cost, potential side effects, or its suitability for their patients. There are four main categories of objections, known as PETE: Price, Effort, Time, and Effectiveness. 2024, August 27). 2024, September 20). 2024, August 28). link] Jacoby, D.

Sales 52

Sales Pharma Pharmaceutical Sales Prospecting 52

pharmaphorum

JULY 11, 2022

The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects.

Engineering 52

Engineering Side effects Competition Sales 52

pharmaphorum

OCTOBER 10, 2022

month mPFS with Keytruda plus chemo, with fewer side effects. That approval was in melanoma, a much smaller patient population than NSCLC, although BMS is already testing Opdualag in NSCLC and other indications, including colorectal cancer, and has predicted it could make annual sales of $4 billion by the end of the decade.

Side effects 59

Side effects Sales Marketing FDA 59

European Pharmaceutical Review

AUGUST 3, 2023

This study has been hailed as a breakthrough as the data show that Leqembi achieved a 27 percent reduction in the progression of Alzheimer’s, provided patients were treated early following the diagnosis of the disease. Under a “usual” EMA assessment timetable, it is likely that Leqembi would not be authorised before Q2 2024.

Food and Drug Administration 52

Food and Drug Administration Medicine FDA Marketing 52

pharmaphorum

JULY 26, 2022

Other late-stage trials on the go include BROOKLYN, which is enrolling adults with HeFH whose LDL cholesterol is not adequately controlled despite being on maximally tolerated lipid-modifying therapies, and a cardiovascular outcomes study in ASCVD patients called PREVAIL. So why will obicetrapib avoid the pitfalls of its predecessors?

Side effects 52

Side effects Safety Pharma Patients 52

PM360

APRIL 22, 2024

For instance, they can report back on unmet medical needs in the market and on prescriber or patient experiences with the standard of care or the product being utilized. Ideally, insights from MSL activities lead to better evidence and more successful development programs and patient outcomes.

Education 52

Education Medical Medical science Customer Relationship Management 52

Pharmaceutical Representative Training

JUNE 22, 2024

Avoiding potentially misleading practices, providing accurate information and prioritizing patient welfare are important concepts reps must follow. Ethical conduct helps maintain the company’s integrity and foster trust with HCPs and patients. Ethical Conduct: In pharma sales, ethical conduct and behavior is crucial.

Sales 52

Sales Pharmaceutical Ethics Pharmaceutical Sales 52

Medico Reach

FEBRUARY 8, 2023

billion during 2020-2024. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. Such results call for stringent vigilance on the medicines quality and after-effects, nudging the emergence of the pharmacovigilance market. from 2023 to 2030.

Pharma 52

Pharma Medicine Marketing Prospecting 52

European Pharmaceutical Review

OCTOBER 3, 2024

Daniel Vitt (DV): A current trend in oral small molecule drug development is a shift towards creating more selective and patient-friendly drugs. In clinical trials, patients treated with Vidofludimus calcium did not show increased rates of infections or infestations compared to placebo.

Safety 52

Safety Pharmaceutical Patients Side effects 52

Pharmaceutical Technology

FEBRUARY 17, 2023

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. For this approach, a “3+3” model is used where a study enrolls three patients into a given dose cohort.

FDA 115

FDA Side effects Pharmacology Patients 115

Pharmaceutical Technology

JUNE 20, 2023

GlobalData forecasts that the market for AI platforms for the entire healthcare industry will reach $4.3bn by 2024, up from $1.5bn in 2019 [i]. Consent documents often describe technical medical conditions and regulatory bodies are increasing pressure on sponsors to ensure that patient-facing information can be easily understood by patients.

Electronics 52

Electronics Medical Healthcare Healthcare 52